Aleafia Labs Partners on Cannabinoid Pharmacogenetics Study
October 30 2018 - 6:00AM
Study with G420, US-Based AKESOgen aimed at
producing genetic tools for improved medical cannabis
therapy
Aleafia Labs, a division of Aleafia Health Inc. (TSXV: ALEF: OTCQX:
ALEAF, FRA: ARAH) (“
Aleafia“) and Guided 420
Genetics Inc. (“
G420”) with U.S.-based AKESOgen,
Inc., (“
AKESOgen”), together the
(“
Parties”), are announcing the commencement of a
joint study (“
the Study”) on cannabinoid
pharmacogenetics in medical cannabis therapy. The initial 200
patient study will focus on developing medical cannabis patient
genetic screening tools in the areas of THC-CBD sensitivity and
metabolism, Endocannabinoid Deficiency Syndrome and cannabis
treatment safety and adverse event risk.
This initiative will be funded by G420 and will
be administered by Aleafia physicians practicing within the Canabo
Medical Clinic network. The Study is expected to generate unique
intellectual property assets that can be used towards proprietary
product development and tools to improve medical cannabis treatment
of major illnesses. It is expected that this study will lead to
additional clinical investigations and larger retrospective cohort
studies as well as prospective clinical trials based on the
indications generated.
“Aleafia is pleased to partner with
G420/AKESOgen in a first of its kind cannabis related
pharmacogenomics study,” said Aleafia President of Clinic
Operations, Dr. Gary Goodyear. “Aleafia’s unique medical cannabis
clinic business perfectly complements a robust clinical research
strategy that should yield benefits to patients through the form of
improved treatment methods and product development.”
“Utilizing pharmacogenetics to better manage
safety and efficacy for the administration of medical cannabis in a
precise manner is a large unmet need in a fast-growing industry,”
added Dr. Mark Bouzyk, AKESOgen’s Chief Scientific
Officer. “The combination of G420/AKESOgen’s resources and
expertise in genetic analysis and genomic study management combined
with Aleafia’s leading clinical footprint in Canada’s medical
cannabis sector has very exciting potential for new knowledge and
therapy applications in this rapidly developing field.”
“Effective genetic screening tools have the
potential to dramatically improve patient outcomes through more
accurate dosing and treatment targeting,” said Aleafia Chief
Medical Officer Dr. Michael Verbora. “This includes application in
opioid replacement therapy and chronic illness treatment such as
those currently used for cancer.”
For Investor & Media Relations, please
contact:Nicholas Bergamini, VP Public Affairs
IR@AleafiaInc.com
About Aleafia Labs:
Aleafia Labs, a division of Aleafia Health Inc.
oversees research & development of unique, proprietary
intellectual property and products in the cannabis field, with a
focus on medical cannabis treatment and cultivation. Aleafia is
uniquely differentiated as a medical cannabis company as the
interaction between the business and patient does not end at the
point of sale. Canabo physicians diagnose, treat and track patients
throughout the entire treatment cycle, a process which has led to
the Company amassing what the company believes is the largest
medical cannabis data set in the world.
About G420:
G420 is a company whose mission is to develop
unique pharmacogenetics products in rapidly emerging personal
health application markets. Pharmacogenetics is a key component in
the growing trend towards more personalized medicine where
individual genetics play a greater role in establishing drug
treatments and therapies. G420’s partner is U.S.-based AKESOgen, a
leading genomics analysis and genetic clinical trial company.
AKESOgen maintains a state of the art CLIA compliant and CAP
accredited laboratory with extensive experience managing and
processing large scale DNA test programs in the U.S. and
internationally.
Neither Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and
information that are based on the beliefs of management and reflect
the Company's current expectations. When used in this press
release, the words "estimate", "project", "belief", "anticipate",
"intend", "expect", "plan", "predict", "may" or "should" and the
negative of these words or such variations thereon or comparable
terminology are intended to identify forward-looking statements and
information. The forward-looking statements and information
in this press release includes information relating to the
implementation of Aleafia Health's business plan. Such
statements and information reflect the current view of the Company
with respect to risks and uncertainties that may cause actual
results to differ materially from those contemplated in those
forward-looking statements and information.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause our
actual results, performance or achievements, or other future
events, to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among
others, the following risks: risks associated with the
implementation of Aleafia Health's business plan and matters
relating thereto, risks associated with the cannabis industry,
competition, regulatory change, the need for additional financing,
reliance on key personnel, the potential for conflicts of interest
among certain officers or directors, and the volatility of the
Company's common share price and volume. Forward-looking
statements are made based on management's beliefs, estimates and
opinions on the date that statements are made and the Company
undertakes no obligation to update forward-looking statements if
these beliefs, estimates and opinions or other circumstances should
change. Investors are cautioned against attributing undue
certainty to forward-looking statements.
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aleafia Health (TSXV:ALEF)
Historical Stock Chart
From Jul 2023 to Jul 2024